Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis

Infection and Immunity

Volumn 66, Issue 5, 1998, Pages 2300-2309

  Zantl, Niko ^a,b   Uebe, Annette ^a,b   Neumann, Brigitte ^a   Wagner, Hermann ^a   Siewert, Jörg Rüdiger ^b   Holzmann, Bernhard ^a,b   Heidecke, Claus Dieter ^b   Pfeffer, Klaus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCENDING COLON; BACTERIAL COLONIZATION; BACTERIAL PERITONITIS; CONTROLLED STUDY; ENDOTOXEMIA; ENTEROCOCCUS; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; INFLAMMATION; INTERFERON INDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STENT; SURVIVAL RATE;

EID: 0031924789     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.5.2300-2309.1998     Document Type: Article

References (66)

1. Abraham, E., M. P. Glauser, T. Butler, J. Garbino, D. Gelmont, P. F. Laterre, K. Kudsk, H. A. Bruining, C. Otto, E. Tobin, C. Zwingelstein, W. Lesslauer, and A. Leighton. 1997. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277:1531-1538.
2. Anonymous. 1992. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20:864-874.
3. Bach, E. A., M. Aguet, and R. D. Schreiber. 1997. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15:563-591.
4. Bagby, G. J., K. J. Plessala, L. A. Wilson, J. J. Thompson, and S. Nelson. 1991. Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J. Infect. Dis. 163:83-88.
5. Baker, C. C., I. H. Chaudry, H. O. Gaines, and A. E. Bane. 1983. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331-335.
6. Beutler, B., and A. Cerami. 1989. The biology of cachectin/TNF - a primary mediator of the host response. Annu. Rev. Immunol. 7:625-655.
7. Beutler, B., I. W. Milsark, and A. C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871.
8. Beutler. B. 1992. Tumor necrosis factors. Raven Press Ltd., New York, N.Y.
9. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:749-795.
10. Bone, R. C. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115:457-469.
11. Bone, R. C. 1996. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann. Intern. Med. 125: 680-687.
12. Bone, R. C. 1996. The sepsis syndrome. Definition and general approach to management. Clin. Chest Med. 17:175-181.
13. Bone, R. C., C. J. Fisher, Jr., T. P. Clemmer, G. J. Slotman, C. A. Metz, and R. A. Balk. 1987. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 317:653-658.
14. Car, B. D., V. M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet, and B, Ryffel. 1994. Interferon gamma receptor deficient mice are resistant to endotoxic shock. J. Exp. Med. 179:1437-1444.
15. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
16. Docke, W. D., F. Randow, U. Syrbe, D. Krausch, K. Asadullah, P. Reinke, H. D. Volk, and W. Kox. 1997. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3:678-681.
17. Echtenacher, B., W. Falk, D. N. Mannel, and P. H. Krammer. 1990. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145:3762-3766.
18. Echtenacher, B., L. Hultner, and D. N. Mannel. 1995. Cellular and molecular mechanisms of TNF protection in septic peritonitis. J. Inflamm. 47:85-89.
19. Echtenacher, B., D. N. Mannel, and L. Hultner. 1996. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77.
20. Erickson, S. L., F. J. de Sauvage, K. Kikly, K. Carver Moore, S. Pitts Meek, N. Gillett, K. C. Sheehan, R. D. Schreiber, D. V. Goeddel, and M. W. Moore. 1994. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372:560-563.
21. Ertel, W., M. H. Morrison, P. Wang, Z. F. Ba, A. Ayala, and I. H. Chaudry. 1991. The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann. Surg. 214:141-148.
22. Eskandari, M. K., G. Bolgos, C. Miller, D. T. Nguyen, L. E. DeForge, and D. G. Remick. 1992. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148:2724-2730.
23. Fischer, E., M. A. Marano, K. J. Van Zee, C. S. Rock, A. S. Hawes, W. A. Thompson, L. DeForge, J. S. Kenney, D. G. Remick, and D. C. Bloedow. 1992. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Eschcrichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J. Clin. Invest. 89:1551-1557.
24. Fisher, C. J., Jr., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334:1697-1702.
25. Fisher, C. J., Jr., J. F. Dhainaut, S. M. Opal. J. P. Pribble, R. A. Balk, G. J. Slotman. T. J. Iberti, E. C. Ratkow. M. J. Shapiro, and R. L. Greenman. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836-1843.
26. Fisher, C. J., Jr., G. J. Slotman, S. M. Opal, J. P. Pribble, R. C. Bone, G. Emmanuel. D. Ng, D. C. Bloedow, and M. A. Catalano. 1994. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit. Care Med. 22:12-21.
27. Fisher, C. J. J., Jr., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. H. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:fc fusion protein. N. Engl. J. Med. 334:1697-1702.
28. Flynn, J. L., M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, R. Schreiber, T. W. Mak, and B. R. Bloom. 1995. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572.
29. Greenman, R. L., R. M. Schein, M. A. Martin, R. P. Wenzel, N. R. MacIntyre, G. Emmanuel, H. Chmel, R. B. Kohler, M. McCarthy, and J. Plouffe. 1991. A controlled clinical trial of E5 murine monoclonal IgM antibody to endutoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266:1097-1102.
30. Heremans, H., J. Van Damme, C. Dillen, R. Dijkmans, and A. Billiau. 1990. Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice. J. Exp. Med. 171:1853-1869.
31. Holzheimer, R. G., M. Schein, and D. H. Wittmann. 1995. Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondary peritonitis. Arch. Surg. 130:1314-1319.
32. Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R. M. Zinkernagel, and M. Aguet. 1993. Immune response in mice that lack the interferon-gamma receptor. Science 259:1742-1745.
33. Kox, W. J., R. C. Bone, D. Krausch, W. D. Docke, S. N. Kox, H. Wauer, K. Egerer, S. Querner, K. Asadullah, R. von Baehr, and H. D. Volk. 1997. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch. Intern. Med. 157:389-393.
34. Lehmann, V., M. A. Freudenberg, and C. Galanos. 1987. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactos-amine-treated mice. J. Exp. Med. 165:657-663.
35. Lembert, A. 1826. Mémoire sur l'enterorrhaphie avec description d'un procède nouveau pour pratiquer cette opération chirurgicale. Répertoire général d'anatomie et de physiologie pathologique et de clinique. Chirurgicale 2:104.
36. Li, L., J. F. Elliott, and T. R. Mosmann. 1994. IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J. Immunol. 153:3967-3978.
37. Mancilla, J., P. Garcia, and C. A. Dinarello. 1993. The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect. Immun. 61:926-932.
38. McMasters, K. M., J. C. Peyton, D. J. Hadjiminas, and W. G. Cheadle. 1994. Endotoxin and tumour necrosis factor do not cause mortality from caecal ligation and puncture. Cytokine 6:530-536.
39. Miethke, T., C. Wahl, K. Heeg, B. Echtenacher, P. H. Krammer, and H. Wagner. 1992. T cell-mediated lethal shock triggered in mice by the super-antigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J. Exp. Med. 175:91-98.
40. Miles, R. H., T. P. Paxton, D. J. Dries, and R. L. Gamelli. 1994. Interferon-gamma increases mortality following cecal ligation and puncture. J. Trauma 36:607-611.
41. Neubauer, H., and K. Pfeffer. Unpublished data.
42. O'Suilleabhain, C., S. T. O'Sullivan, J. L. Kelly, J. Lederer, J. A. Mannick, and M. L. Rodrick. 1996. Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury. Surgery 120:290-296.
43. Pfeffer, K., T. Matsuyama, T. M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Kronke, and T. W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467.
44. Piper, R. D., D. J. Cook, R. C. Bone, and W. J. Sibbald. 1996. Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit. Care Med. 24:2059-2070.
45. Rajewsky, K., H. Gu, R. Kuhn, U. A. Betz, W. Muller, J. Roes, and F. Schwenk. 1996. Conditional gene targeting. J. Clin. Invest. 98:600-603.
46. Remick, D. G. 1995. Applied molecular biology of sepsis. J. Crit. Care 10:198-212.
47. Rennick, D. M., M. M. Fort, and N. J. Davidson. 1997. Studies with IL-10-/-mice: an overview. J. Leukocyte Biol. 61:389-396.
48. Rietschel, E. T., H. Brade, O. Holst, L. Brade, S. Muller-Loennies, U. Marmat, U. Zahringer, F. Beckmann, U. Seydel, K. Brandenburg, A. J. Ulmer, T. Mattern, H. Heine, J. Schletter. H. Loppnow, U. Schonbeck, H. D. Flad, S. Hauschildt, U. F. Schade, F. di Padova, et al. 1996. Bacterial endotoxin: chemical constitution, biological recognition, host response, and immunological detoxification. Curr. Top. Microbiol. Immunol. 216:39-81.
49. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802.
50. Russell, D. A., and R. C. Thompson. 1993. Targets for sepsis therapies: tumor necrosis factor versus interleukin-1. Curr. Opin. Biotechnol. 4:714-721.
51. Sanchez-Madrid. F., P. Simon, S. Thompson, and T. A. Springer. 1983. Mapping of antigenic and functional epitopes on the alpha- and beta-subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and Mac-1. J. Exp. Med. 158:586-602.
52. Smith, C. A., T. Farrah, and R. G. Goodwin. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76:959-962.
53. Tracey, K. J., B. Beutler, S. F. Lowry, J. Merryweather, S. Wolpe, I. W. Milsark, R. J. Hariri, T. J. Fahey. A. Zentella, J. D. Albert, et al. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474.
54. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664.
55. Trinchieri, G. 1997. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma). Curr. Opin. Immunol. 9:17-23.
56. van den Broek, M. F., U. Muller, S. Huang, R. M. Zinkernagel, and M. Aguet. 1995. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148:5-18.
57. Van Zee, K. J., L. L. Moldawer, H. S. Oldenburg, W. A. Thompson, S. A. Stackpole, W. J. Montegut, M. A. Rogy, C. Meschter, H. Gallati, C. D. Schiller, W. F. Richter, H. Loetscher, A. Ashkenazi, S. M. Chamow, F. Wurm, S. E. Calvano, S. F. Lowry, and W. Lesslauer. 1996. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J. Immunol. 156:2221-2230.
58. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411-452.
59. Volk, H. D., P. Reinke, D. Krausch, H. Zuckermann, K. Asadullah, J. M. Muller, W. D. Docke, and W. J. Kox. 1996. Monocyte deactivation-ratio-nale for a new therapeutic strategy in sepsis. Intensive Care Med. 22(Suppl. 4):474-481.
60. Warren, H. S. 1997. Strategies for the treatment of sepsis. N. Engl. J. Med. 336:952-953.
61. Wichtermann, K. A., A. E. Baue, and I. H. Chaudry. 1980. Sepsis and septic shock - a review of laboratory models and a proposal. J. Surg. Res. 29:189-201.
62. Zantl, N., and B. Holzmann. Unpublished data.
63. Zantl, N., and K. Pfeffer. Unpublished data.
64. Zantl, N., B. Holzmann, C.-D. Heidecke, and K. Pfeffer. Unpublished data.
65. Zantl, N., B. Holzmann, K. Pfeffer, and C.-D. Heidecke. 1997. Colon ascendens stent peritonitis (CASP): a novel surgical model for the induction of bacterial peritonitis/sepsis in mice, p. 467-171. In E. Faist (ed.), The immune consequences of trauma, shock and sepsis. Monduzzi Editore, Bologna, Italy.
66. Ziegler, E. J., C. J. Fisher, Jr., C. L. Sprung, R. C. Straube, J. C. Sadoff, G. E. Foulke, C. H. Wortel, M. P. Fink, R. P. Dellinger, and N. N. Teng. 1991. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 324:429-436.